CC
AUTL

Covalis Capital’s Autolus Therapeutics AUTL Stock Holding History

Covalis Capital’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-67,767
Closed -$129K – 38
2022
Q4 		$129K Buy
+67,767
New +$171K 0.03% 50

Other funds holding AUTL

SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
OAMG
Odey Asset Management Group London, United Kingdom $381M AUM 45.36% 1-Year Est. Return
PL
Perpetual Ltd Sydney, New South Wales, Australia $7B AUM 19.75% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Covalis Capital's AUTL Position: Q1 2023 in Review

Covalis Capital sold out of Autolus Therapeutics (AUTL) in Q1 2023, closing a stake of 67,767 shares — an estimated $129K sold.

Covalis Capital first reported a position in AUTL in Q4 2022 and held it in 1 quarter. The position peaked at $129K in Q4 2022. 65 funds tracked by Wall St. Rank hold AUTL as of Q1 2023.

  • Covalis Capital reported no remaining Autolus Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Covalis Capital sold 67,767 Autolus Therapeutics shares in Q1 2023, an estimated $129K.
  • Covalis Capital first reported a position in Autolus Therapeutics in Q4 2022 and held it in 1 quarter.
  • Covalis Capital's Autolus Therapeutics position peaked at $129K in Q4 2022.
  • 65 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q1 2023.

Based on Covalis Capital's 13F filing for Q1 2023, filed 15 May 2023.